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Abstract
For many years Phase I and Phase II clinical trials were conducted separately, but there
was a recent shift to combine these Phases. While a variety of Phase I/II model-based designs
for cytotoxic agents were proposed in the literature, methods for molecularly targeted agents
(TA) are just starting to develop. The main challenge of the TA setting is the unknown dose-
efficacy relation that can have either an increasing, plateau or umbrella shape. To capture
these, approaches with more parameters are needed to model the dose-efficacy relationship
or, alternatively, more orderings of the dose-efficacy relationship are required to account for
the uncertainty in the curve shape. As a result, designs for more complex clinical trials,
for example, trials looking at schedules of a combination treatment involving TA, have not
been extensively studied yet. We propose a novel regimen-finding design which is based
on a derived efficacy-toxicity trade-off function. Due to its special properties, an accurate
regimen selection can be achieved without any parametric or monotonicity assumptions. We
illustrate how this design can be applied in the context of a complex combination-schedule
clinical trial. We discuss practical and ethical issues such as coherence, delayed and missing
efficacy responses, safety and futility constraints.
1 Introduction
The primary objective of a Phase I trial is to identify the maximum tolerated regimen (dose,
combination, schedule, etc.), that is the regimen corresponding to the highest acceptable toxicity
probability φ. Subsequently, a Phase II clinical trial with the objective to find a safe regimen
corresponding to a pre-specified efficacy probability is planned. For many years these phases
were conducted separately, but there was a recent shift to integrate both Phase I and Phase II
clinical trials in a single study. The integration of Phases allows to accelerate the development
and reduces costs (Yin, 2013; Wages and Conaway, 2014) while more observations for both
toxicity and efficacy endpoints become available. The goal of a Phase I/II clinical trial is to
find the so-called optimal biologic regimen (OBR). There are different definitions of the OBR
which depend on the context of the trial. The OBR can be defined as the safest regimen with a
toxicity probability below the upper toxicity bound φ and a maximum efficacy above the lowest
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efficacy bound ψ (see e.g. Riviere et al., 2016). It can, however, be challenging to find a single
regimen having the safest toxicity and maximum efficacy simultaneously. In this case, the OBR
can be alternatively defined as the regimen with the highest efficacy rate while still safeguarding
patients (see e.g. Wages and Tait (2015)). In this work we use both definitions and call the
regimen satisfying the first definition the optimal regimen and the regimen satisfying the second
definition the correct regimen.
Historically, Gooley et al. (1994) was one of the first to consider two dose-outcome models.
Similar to later works on Phase I/II clinical trials (e.g. Thall and Russell, 1998; O’Quigley et al.,
2001; Braun, 2002; Thall and Cook, 2004; Yin et al., 2006, among others), this design is based on
the paradigm ‘the more the better‘ - i.e. an agent has a greater activity but also a greater toxicity
as the dose increases. This holds for cytotoxic agents, but can be violated for molecularly targeted
agents (TA) which include hormone therapies, signal transduction inhibitors, gene expression
modulators, apoptosis inducers, angiogenesis inhibitors, immunotherapies, and toxin delivery
molecules, among others. For a TA either efficacy or toxicity curves can have a plateau (Morgan
et al., 2003; Postel-Vinay et al., 2011; Robert et al., 2014; Paoletti et al., 2014) or exhibit an
umbrella shape (Conolly and Lutz, 2004; Lagarde et al., 2015).
Several designs for either single agent or combination therapy trials that relax the assumption
of monotonicity for the dose-efficacy relationship have been proposed in the literature: see e.g.
Polley and Cheung (2008); Hoering et al. (2013); Yin et al. (2013); Zang et al. (2014); Cai et al.
(2014); Wages and Tait (2015); Riviere et al. (2016) for a binary efficacy endpoint and Hirakawa
(2012); Yeung et al. (2015, 2017) for a continuous efficacy endpoint. The majority of current
proposed designs are model-based and the selection of the OBR is governed either by (i) a trade-
off function (e.g. Thall and Cook, 2004; Yeung et al., 2015, 2017) or (ii) a two-stage procedure in
which the safe subset is firstly defined and the most efficacious dose is then estimated (e.g. Thall
and Russell, 1998; Yin et al., 2013; Wages and Tait, 2015). Regardless of the approach used,
the number of parameters to be included in the underlying model increases considerably if the
monotonicity assumption is relaxed (Cai et al., 2014; Riviere et al., 2016). The design proposed
by Wages and Tait (2015) employs a one parameter model, but uses the idea of different orderings
(Wages et al., 2011) to overcome the uncertainty about monotonicity. This idea can be extended
to a range of problems (see e.g. Wages and Conaway, 2014, for cytotoxic drugs combination
trials), although the extension to more complex settings, for instance, combination-schedule
trials, can also be challenging due a large number of possible orderings. Consequently, designs
for such more complex trials have not been extensively studied yet. In contrast, an approach
that does not use any parametric or monotonicity assumptions gives more flexibility and is a
good candidate for both simple and complex Phase I/II clinical trials.
This work is motivated by an ongoing Phase I clinical trial at the Hospital Gustave Roussy
for patients with high-risk neuroblastoma, for which the authors contributed as statistical col-
laborators. Neuroblastoma is the most frequent individual type of solid tumour in children
(Steliarova-Foucher et al., 2017). Although different chemotherapy regimens of increasing inten-
sities have been evaluated, the 5-years overall survival remains around 50% for the high risk group
(Kreissman et al., 2013). A recent pre-clinical study has suggested that the use of a particular
immunotherapy targeting the disialoganglioside GD2 which is expressed in all neuroblastoma
cells, in combination with conventional chemotherapy (etoposide and cisplatin) can improve the
induction treatment. The first part of the high-risk neuroblastoma treatment aims to reduce
the tumour burden to facilitate surgery and subsequent treatments. Combinations of the newly
developed immunotherapy and chemotherapy are given under different schedules:
• Immunotherapy for 2 days after the chemotherapy (S1)
• Immunotherapy for 3 days after the chemotherapy (S2)
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Table 1: The range of considered regimens in the motivating trial.
Regimen T1 T2 T3 T4 T5 T6
Cycle 1 S1 S2 S3 S3 S4
Cycle 2 S1 S2 S2 S3 S4 S4
• Immunotherapy for 4 days together with the chemotherapy. Overlap 1 day (S3)
• Immunotherapy for 4 days together with the chemotherapy. Overlap 2 days (S4)
The combination of treatments is given for two cycles (three weeks). In each cycle the combina-
tion is given under one of schedules S1, . . . , S4. Six different regimens are considered in the study
and are given in Table 1. The toxicity outcome is evaluated by the end of the second cycle. The
efficacy data is available after two more cycles (after six weeks from the start of the treatment)
only. If a patient has experienced toxicity he will be treated off the protocol and the efficacy
outcome cannot be observed. A maximum of 40 patients will be recruited to the study and it is
anticipated that two patients can be recruited each month. Consequently, it is expected that the
next two patients are assigned a regimen before efficacy outcomes for the previous two patients
are observed.
Clinician are certain that toxicity probabilities of T3, T4 and T5 are greater than of T1, T2
and smaller than of T6. However, toxicity probabilities of T3, T4 and T5 cannot be put in the
order of the increasing toxicity before the trial. Therefore, there are 6 possibilities how regimens
T1, . . . , T6 can be ordered with respect to the toxicity probabilities
1) T1, T2, T3, T4, T5, T6
2) T1, T2, T3, T5, T4, T6
3) T1, T2, T4, T3, T5, T6
4) T1, T2, T4, T5, T3, T6
5) T1, T2, T5, T3, T4, T6
6) T1, T2, T5, T4, T3, T6
(1)
Additionally, a plateau or umbrella shape for the efficacy is plausible due to the novel agent
mechanism. This results in 48 efficacy orderings to be considered so that traditional designs
cannot be applied directly.
The aim of this paper is to propose a practical Phase I/II design that can be used for regimens
with both monotonic and non-monotonic regimen-toxicity and regimen-efficacy relationships. We
derive a novel trade-off criterion that governs the regimen selection during the study. The form
of the proposed trade-off function is motivated by the recent developments in the theory of the
weighted information measures (Mozgunov and Jaki, 2017) and in the estimation on restricted
parameter spaces (Mozgunov et al., 2017). While model-based estimates can be used together
with the proposed trade-off function, we show that a highly accurate optimal and correct regimens
recommendations can be achieved without parametric assumptions due to the trade-off function’s
special properties. It is demonstrated how practical issues such as safety, futility or information
about any pair of the regimens can be incorporated in the proposed design.
The rest of the paper is organised as follows. The information-theoretic approach, the trade-
off function and its estimation are given in Section 2. The novel dose-finding design and its
illustration are presented in Section 3. Safety and futility constraints are introduced in Section
4. Section 5 presents the application of the proposed design to the motivating trial. Further
discussion is given in Section 6.
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2 Methods
2.1 Trade-off function
Following Mozgunov and Jaki (2017), let us consider a random variable Y that takes one of three
values corresponding to (i) ‘efficacy and no toxicity‘, (ii) ‘no efficacy and no toxicity‘ and (iii)
‘toxicity‘. Outcomes ‘toxicity and no efficacy‘ and ‘toxicity and efficacy‘ are combined as efficacy
can only be observed when no toxicity occurs. Let Z =
[
Z(1), Z(2), Z(3)
] ∈ S2 be a random
probability vector defined on the triangle
S2 = {Z : Z(1) > 0, Z(2) > 0, Z(3) > 0;
3∑
i=1
Z(i) = 1}.
Random variables Z(1), Z(2), Z(3) correspond to probabilities of each of the three outcomes. As∑3
i=1 Z
(i) = 1, the problem is, indeed, two-dimensional. A common question in a Phase I/II
trial is ‘what is the probability vector Z’. We use a Bayesian framework to answer this question.
Assume that Z has a prior Dirichlet distribution Dir(v + J), v = [v1, v2, v3]
T ∈ R3+ where
vi > 0, i = 1, 2, 3 and J is a 3-dimensional unit vector. After n realisations in which xi outcomes
of i, i = 1, 2, 3 are observed, the posterior probability density function fn of a random vector
Z(n) takes the Dirichlet form
fn(p|x) = 1
B(x+ v+ J)
3∏
i=1
pxi+νii (2)
where p = [p1, p2, p3]
T
, x = [x1, x2, x3],
∑3
i=1 xi = n, 0 < pi < 1,
∑3
i=1 pi = 1 and
B(x+ v+ J) =
∏3
i=1 Γ(xi + vi + 1)
Γ
(∑3
i=1(xi + vi + 1)
)
is the Beta-function and Γ(x) is the Gamma-function. The quantitative amount of information
required to answer the estimation question can be measured by the Shannon differential entropy
of fn (Cover and Thomas, 2012)
h(fn) = −
∫
S2
fn(p|x)logfn(p|x)dp (3)
with convention 0 log 0 = 0. However, an investigator has a particular interest in regimens which
are associated with desirable efficacy and acceptable toxicity probabilities and the measure (3)
does take this into account (Kelbert et al., 2016).
Assume that the OBR is defined as the regimen with probabilities of the three outcomes equal
γ = [γ1, γ2, γ3] ∈ S2 where γ1, γ2, γ3 are the target probabilities of ‘no toxicity and efficacy‘,
‘no toxicity and no efficacy‘ and ‘toxicity‘, respectively. These target characteristics are to be
defined by clinicians. Then, one would like to find the regimen which characteristics (probability
of these events) as close as possible to the targets. Due to the specific interest in the regimens
with characteristics close to γ, let us consider a two-fold experiment in which, when the sample
size is large, an investigator seeks to answers (i) what the probability vector is; while for the
small sample size he is interested in (ii) whether the probability vector lies in the neighbourhood
of γ so that subsequent patients can be allocated to regimens with the characteristics close to
the OBR’s ones. The amount of the information required for this two-fold experiment can be
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measured by the weighted Shannon differential entropy (Belis and Guiasu, 1968; Clim, 2008;
Kelbert and Mozgunov, 2015; Kelbert et al., 2016) of fn with a positive weight function φn(p)
hφn(fn) = −
∫
S2
φn(p)fn(p|x)logfn(p|x)dp. (4)
The weight function φn(p) emphasises an interest in the neighbourhood of γ rather than on the
whole space. We will use a weight function of the Dirichlet form,
φn(p) = C(x,γ, n)
3∏
i=1
p
γi
√
n
i (5)
where the rate of
√
n emphasises an interest in question (ii) for the small sample size only. Here
C(x,γ, n) is a constant that is chosen to satisfy the normalization condition
∫
S2 φn(p)fn(p|x)dp =
1.
Due to ethical constraints and a limited sample size, an investigator is interested in the
accurate estimation not for all regimens, but only for those with characteristics close to the
target. This goal corresponds to questions (ii) alone. The quantitative measure of the informa-
tion required to answer (ii) only equals the difference of weighted hφn(fn) and standard h(fn)
differential entropies (Mozgunov and Jaki, 2017). Denote the vector in the neighbourhood of
which the probability density function fn concentrates as n → ∞ by θ = [θ1, θ2]T, where θ1 is
the probability of ‘efficacy and no toxicity‘, θ2 is the probability of ‘no efficacy and no toxicity‘,
1 − θ1 − θ2 is the probability of toxicity with corresponding targets γ1, γ2, 1 − γ1 − γ2. It was
shown by Mozgunov and Jaki (2017) that the difference of the entropies tends to
δ (θ,γ) :=
γ21
θ1
+
γ22
θ2
+
(1− γ1 − γ2)2
1− θ1 − θ2 − 1, as n→∞, (6)
the sum of three contributions corresponding to each of three events considered.
Although, the result (6) is limiting, we propose to use this quantity as a measure of distance
between θ and γ and, consequently, as a trade-off function for selecting a regimen. Clearly,
δ(·) ≥ 0, δ(·) = 0 iff θ = γ and boundary values θi = 0, i = 1, 2 or θ1 + θ2 = 1 correspond to
infinite values δ(·). The former property is argued to be fundamental for restricted parameter
spaces (Aitchison, 1992; Mateu i Figueras et al., 2013; Mozgunov et al., 2017) and enables to
avoid parametric assumptions. Terms in (6) have the following interpretations:
• When θ1 tends to 0 the regimen is either inefficacious or (and) highly toxic. Then, the value
of the trade-off function tends to infinity meaning that the treatment should be avoided.
• When θ2 tends 0 the regimen is either highly efficacious or (and) highly toxic. Then, this
term penalises the high toxicity regardless of high efficacy as the trade-off function tends
to infinity. This term prevents too quick escalation to highly toxic regimens.
• When 1 − θ1 − θ2 tends 0, the regimen is associated with nearly no toxicity. However,
the optimal regimen is expected to be associated with non-zero toxicity. Then, this terms
drives dose allocation away from the underdosing regimens.
Note that all terms are dependent - an increase in one leads to decreases in others. The opti-
mal value is attained at the point of target characteristics only. The denominators drive away
the selection from inefficacious and highly toxic regimens and concentrate the allocation in the
neighbourhood of the OBR.
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The trade-off function (6) depends on probabilities θ1 and θ2 while the goal of a Phase I/II
clinical trial is conventionally formulated in terms of toxicity (αt) and efficacy (αe) probabilities
and corresponding targets γt and γe. Thus, we re-parametrise (6) using θ1 = (1 − αt)αe, θ2 =
(1 − αt)(1 − αe), γ1 = (1 − γt)γe and γ2 = (1 − γt)(1 − γe) and denote the trade-off function
by δ (αt, αe, γt, γe). This measure can be computed for each of the M regimens under study
with parameters αt,1, . . . , αt,M and αe,1, . . . , αe,M , respectively. Given δ(αt,i, αe,i, γt, γe), i =
1, . . . ,M , the target regimen j satisfies
δ(αt,j , αe,j , γt, γe) = min
i=1,...,M
δ(αt,i, αe,i, γt, γe). (7)
Efficacy-toxicity trade-off contours for different combinations of toxicity and efficacy proba-
bilities and γt = 0.01, γe = 0.99 are given in Figure 1. The contours of the trade-off function are
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Figure 1: Contours of the efficacy-toxicity trade-off function δ(αt, αe, γt, γe) for αt ∈ (0, 0.85)
and αe ∈ (0.15, 1), γt = 0.01, γe = 0.99.
concave. The most desirable point αt = 0.01, αe = 0.99 (right bottom corner) corresponds to
the minimum of the trade-off function. As probabilities move away from this point the trade-off
function grows with an increasing rate that can be seen by contours located closer to each other.
2.2 Estimation
The proposed trade-off function for regimen i depends on unknown parameters αt,i and αe,i.
While these could be estimated using model-based approaches such as the continual reassess-
ment method (O’Quigley et al., 1990), we can also consider each toxicity and efficacy probability
independently as a Beta random variable estimated directly from the observed number of toxi-
cities/efficacies. This allows the design to avoid the monotonicity assumption which motivated
this work initially.
Let us consider an estimator for regimen i. The toxicity probability has prior distribution
B(νt,i + 1, βt,i − νt,i + 1), νt,i, βt,i > 0. After ni patients and xt,i toxicities, we obtain the Beta
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posterior B(xt,i + νt,i + 1, ni − xt,i + βt,i − νt,i + 1) which concentrates in the neighbourhood of
0 < αt,i < 1. Similarly, given prior Beta parameters νe,i, βe,i > 0 and xe,i efficacy responses the
Beta posterior, B(xe,i + νe,i + 1, ni − xe,i + βe,i − νe,i + 1), for the efficacy probability can be
found. The posterior modes of these Beta distributions are
pˆ
(ni)
t,i =
xt,i + νt,i
ni + βt,i
and pˆ
(ni)
e,i =
xe,i + νe,i.
ni + βe,i
, (8)
respectively. We then use the ‘plug-in‘ estimator δ(pˆ
(ni)
t,i , pˆ
(ni)
e,i , γt, γe) = δˆ
(ni)
i as the criterion that
governs the selection of a subsequent regimen to be studied in a Phase I/II regime-finding trial.
We would like to emphasize that the trade-off function (6) is derived in the general form
without assuming independence between toxicity and efficacy. While the estimators (8) does not
account for the interaction between toxicity and efficacy, the derived trade-off function does. The
independent estimates are used to avoid a monotonicity assumption, but the trade-off function
in the derived form allows any estimator to be applied.
3 Regimen-finding algorithm
3.1 Non-randomised design
We propose the following novel regimen-finding design that does not require the assumption of
monotonicity for trials looking to identify a regimen with toxicity probability γt and efficacy
probability γe. Assume that N patients and M regimens are available in a trial. Patients
are assigned sequentially cohort-by-cohort, where a cohort is a small group of typically 1 to 4
patients. Let δˆ
(ni)
i be the ‘plug-in‘ estimator for regimen i after ni patients have been treated
on regimen i. The procedure starts from δˆ
(0)
i and the starting regimen depends on the prior
only. After ni patients on regimen i (i = 1, . . . ,M) the next cohort of patients is allocated to a
regimen m such that
δˆ(nm)m = min
i=1,...,M
δˆ
(ni)
i . (9)
The method proceeds until the maximum number of patients, N , have been treated. We adopt
the regimen selected after N patients as the final recommended regimen.
Note that the estimators in (8) require a vector of prior probabilities for each regimen to be
specified before the trial. This choice implies a specific ordering of the regimens before trial data
are available and can be considered as an initial ordering. However, as the trial progresses this
ordering can change. We refer to the proposed design as ‘WE‘ which stands for the weighted
entropy which motivated the criterion.
3.2 Randomized design
For the WE design all previous outcomes are taken into account for the current selection decision.
In this case designs can ‘lock-in‘ which means that one regimen would be tested regardless of
further outcomes and the true optimal regimen can be never tested. It might happen due to
certain sequences of observations in combination with the choice of the prior. Thus, one can
benefit from the allocation rule based on a randomization (Thall and Wathen, 2007; Wages and
Tait, 2015). We propose randomization within a safety set with probabilities proportional to the
inverse of the trade-off function. For ethical considerations we restrict randomization to the two
best regimens only. Formally, assume that regimen m is the estimated best regimen (has the
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minimum value of δˆ
(nm)
m ) and j is the second best regimen (i.e. has the second smallest value of
δˆ
(nj)
j ). Then, randomization probabilities wˆ
(ni)
i for a regimen i = 1, . . . ,M are
wˆ
(ni)
i =

1/δˆ
(ni)
i
1/δˆ
(nm)
m +1/δˆ
(nj)
j
, if i = m, j and δˆ
(nm)
m , δˆ
(nj)
j 6= 0.
1, if δˆ
(ni)
i = 0.
0, otherwise.
(10)
The method proceeds until the maximum number of patients, N , have been treated. The regimen
m satisfying (9) is adopted as the final recommendation. We refer to this design as ‘WE(R)‘.
This randomization technique allows to get more spread allocation, while assigning only few
patients to suboptimal regimens. We will focus on these two allocation rules only although other
alternatives are possible. For instance, one might assign the first patients using randomization
and the rest using allocation to the ‘best‘ as suggested by Wages and Tait (2015).
3.3 Delayed responses
So far, it was implied that efficacy responses are available at the same time as the toxicity
information is. However, in practice this is unlikely to be true. While toxicity is usually quickly
ascertainable, the efficacy endpoint may take longer to be observed (Riviere et al., 2016) and
waiting for both endpoints increases the length of a trial substantially. However, the proposed
criterion still can be applied in the trial with delayed responses as pˆ
(ni)
t,i and pˆ
(ni)
e,i can be estimated
based on a different number of observations. Consequently, the design can proceed before the
full response is observed and would only use the information available at the time the regimen
for the next cohort is selected.
For instance, in the motivating trial it takes twice as long to observe the efficacy outcome
than the toxicity outcome (six weeks versus three weeks). To conduct the trial in a timely
manner, the next cohort of patients is expected to be assigned based on the toxicity data only
for the previous cohort and both toxicity and efficacy data for earlier patients. For instance,
the recommendation for the third cohort is based on both toxicity and efficacy outcomes for
cohort 1 but only the toxicity outcomes for cohort 2. The proposed design accommodates this
by computing toxicity and efficacy estimates based on different numbers of observations, but
on all the available information up to the time of the next patient allocation. Note that if an
efficacy outcome is available earlier, it can (and should) be included in the design. Doing so
can improve the performance of the design as illustrated in the supplementary materials. Note
also that there may be situations in which auxiliary information about efficacy is available (e.g.
through a short-term endpoint). Accounting for this information is beyond the scope of this
manuscript.
3.4 Coherence
In practice, a clinician might be very cautious about further escalation if a toxicity was observed
in the previous cohort. For this reason, we force the WE designs to satisfy principles of the
coherent escalation/de-escalation (Cheung, 2005) with respect to known orderings. Assume that
there are S known monotonic partial orderings. Denote the position of a regimen for cohort i
in the partial ordering s by [s]T
(i) and the sum of the corresponding toxicity outcomes by Q(i).
Then the coherent escalation means that,
P
(
[s]T
(i) −[s] T (i−1) > 0|Q(i−1) ≥ q
)
= 0, s ∈ S (11)
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where q is a threshold number of toxicities after which the escalation should be prohibited. The
coherent de-escalation means that
P
(
[s]T
(i) −[s] T (i−1) < 0|Q(i−1) < q
)
= 0, s ∈ S. (12)
For instance, in the motivating example the following partial orderings are known
αt,1 ≤ αt,2 ≤ αt,3 ≤ αt,6
αt,1 ≤ αt,2 ≤ αt,4 ≤ αt,6 (13)
αt,1 ≤ αt,2 ≤ αt,5 ≤ αt,6.
It follows that if more than q toxicity outcomes are observed for T3 the next cohort can be still
allocated to T4. Moreover, this coherence principles are used to incorporate the information
about pairs of regimens that can be ordered (for example T1 and T2). While it is not taken into
account in the estimation step of the original design, it is reflected in allocation restrictions.
3.5 Illustration
Below, we demonstrate the performance of the non-randomized WE design in the context of the
motivating trial. The major challenge of the motivating trial is the uncertainty in the regimen-
toxicity relation for T3, T4, T5 which results in six possible toxicity orderings (1). Furthermore,
for each of these toxicity orderings either a monotonic, plateau or umbrella regimen-efficacy
relationship can be expected. Despite this complex setting, the WE design can be applied as
both toxicity and efficacy endpoints are binary.
We consider the regimen-finding clinical trial with M = 6 regimens, T1, . . . , T6, N = 36
patients and cohort size c = 2. The regimens are ordered (on the basis of clincians believe) with
increasing toxicity and efficacy. The trial is to be started at regimen T1 and no regimen-skipping
is allowed. The coherence parameter is fixed to be q = 1 and the escalation/de-escalation is
required to be coherent with respect to known partial orderings (13). Following the motivating
trial, toxicity is evaluated after two cycles of treatment (three weeks) and efficacy data is available
after four cycles (six weeks) only. Since it is expected to recruit one patient per month, we assume
that the next patient is assigned after the toxicity outcome is available for the previous patient.
Moreover, efficacy is only observed for patients without toxicity.
True probabilities of toxicity and efficacy are αt = [0.05, 0.10, 0.45, 0.15, 0.30, 0.55]
T and αe =
[0.10, 0.40, 0.70, 0.70, 0.70, 0.70]T. This scenario corresponds to a plateau in the regimen-efficacy
relationship starting at T3 and to the misspecified ordering of toxicities − regimen T3 is more
toxic than regimens T4 and T5. We study the ability of the WE design to recommend the
optimal and correct regimens. The safest regimen with a toxicity probability below the upper
toxicity bound φ and a maximum efficacy above the lowest efficacy bound ψ is called optimal
and the regimen with the highest efficacy rate while still safeguarding patients (irrespective of it
also having lowest toxicity) is called correct. Then, for a maximum toxicity probability bound
φ = 0.35 and a minimum efficacy probability bound ψ = 0.20, regimen T4 is the optimal one and
regimens T4 and T5 are correct regimens. To ensure that a regimen with the same efficacy but
lower toxicity is preferred over one with higher toxicity we set γt = 0.01 and, similarly, we set
γe = 0.99 to prefer a regimen with a higher efficacy if the toxicity is the same. To see that T4 is
indeed the OBR using these targets, one can compute the true values of the trade-off function
[9.48,1.77,1.59,0.67,1.03,2.16]T. The minimum among all regimes corresponds to T4 as desired
and the second smallest value corresponds to the correct regimen T5.
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Prior parameters of toxicity
pˆ
(0)
t = [0.10, 0.175, 0.25, 0.325, 0.40, 0.475]
T,
efficacy
pˆ(0)e = [0.60, 0.65, 0.70, 0.75, 0.80, 0.85]
T
and βt,i = βe,i = 1, i = 1, . . . , 6 are chosen. Note that the purpose of this priors is to specify in
which order the regimens are trialled. The allocation of 18 cohorts in a single simulated trial is
given in Figure 2. Note that ‘no toxicity and efficacy‘ and ‘no toxicity and no efficacy‘ outcomes
Individual trial
cohort
 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
R
eg
.1
R
eg
.2
R
eg
.3
R
eg
.4
R
eg
.5
R
eg
.6
No Toxicity + No Efficacy                   
 
Toxicity
 
No Toxicity + Efficacy
Figure 2: Allocation of 18 cohorts in the invididual trial.  corresponds to ‘no toxicity and no
efficacy‘, ? to ‘toxicity‘ and  to ‘no toxicity and efficacy‘ responses.
in Figure 2 can be observed after four cycles only. Until an efficacy outcome is available the
design uses information about ‘no toxicity‘ only.
The allocation starts at T1 with no toxicities. As no efficacy has been observed yet and T1
has ‘promising‘ prior efficacy probability, it is selected again. Following no efficacies for cohort
1, cohort 3 is assigned to T2 at which no patients have toxicities. This leads to selecting T2 again
until the efficacy data are available. After no toxicity (cohort 4) and no efficacy (cohort 3), cohort
5 is assigned to T3 for which both patients experience toxicities. As there is uncertainty whether
T3 is more toxic than T4 and (or) T5, cohort 6 is assigned to T4. After no toxicity outcomes
are observed, cohort 7 is allocated to regimen T4 again. Due to no toxicity (cohort 7) and one
efficacy (cohort 6), regimen T4 is chosen for cohort 8 as well. However, after no efficacy for cohort
7, the design escalates to regimen T5. Again, as no toxicity outcomes are observed for cohort 9,
cohort 10 is assigned to T5 too at which one patient experiences a toxicity. However, by the time
cohort 11 is allocated, an efficacy outcomes for cohort 9 becomes available and the allocation
remains at regimen T5. As no further efficacy has been observed for regimen T5, design escalates
further to regimen T6 for which two toxicities are observed. Then, the design de-escalates to the
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optimal regimen T4 for which one efficacy and no toxicity has been previously observed (against
1 efficacy and 1 toxicity for regimen T5). All the consequent patients (up to cohort 18) are
assigned to the optimal regimen T4 which is finally recommended in the trial. Clearly, a delayed
efficacy response requires two cohort to be assigned to each dose conditionally on ‘no toxicity‘.
It leads to fewer patients at the OBR, but also to more reliable recommendation due to better
exploration of the available regimes.
While the regimen-finding algorithm in an individual trial is considered above, allocation
probabilities for each cohort in 106 replicated trials are given in Figure 3. Using the WE design,
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Figure 3: Probabilities to allocate each of 18 cohorts to T1 (solid green), T2 (dashed green), T3
(dashed red), T4 (solid blue), T5 (dashed blue) and T6 (solid red) in the motivating trial setting.
The optimal regimen is Regimen T4 and the correct regimens are Regimens T4 and T5. Results
are based on 106 replications.
first and second cohorts are to be assigned to the first regimen with probability 1. As it illustrated
above, the design stays at T1 if no toxicity was observed (due to a ‘promising‘ efficacy) or if a
toxicity is observed (due to the coherence principle). The probability to allocate a cohort to
the optimal regimen T4 starts to increase after cohort 5 and reaches nearly 60% for cohort 18.
Considering the probability of regimen recommendations, we compare the performance to an
equal allocation of 6 patients per each regimen. For the equal allocation, the trade-off functions
for each regimen are estimated at the end of the trial and the dose with a smallest value is
recommended. The optimal regimen T4 is recommended in 62.5% of trials and the correct
regimen T5 in 18.6% of trials by the WE design against 31% and 29% by an equal allocation,
respectively. It means that the proposed design recommends one of the correct regimens in more
than 80% of the trials and clearly favours the optimal one.
Overall, the proposed design appears to be able to recommend the optimal regimen with
high probability and the escalation/de-escalation algorithm in the individual trial is intuitive.
A comprehensive study comparing the proposed method to alternative approaches and across
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different scenarios is given in Section 5.
4 Ethical constraints
Not borrowing information across regimens is a key feature of the proposed design. However,
some regimens might have high toxicity and/or low efficacy. Then, a design can result in a high
(small) number of toxicity (efficacy) responses or in an unsafe/inefficacious recommendation. For
ethical reasons it is required to control the number of patients exposed to such regimens and two
time-varying constraints are introduced.
4.1 Safety constraint
Absence of the monotonicity assumption for toxicity makes the problem of the highly toxic
regimen selection even more crucial. A conventional (constant) safety constraint (e.g. as in
Riviere et al., 2016) cannot be applied because no parametric model is used (Mozgunov and Jaki,
2017). On the one hand, a reliable safety constraint should give the hypothetical possibility to
test all regimens if data suggests so. On the other hand, a recommendation should be made with
a high confidence in safety. A time-varying safety constraint meets both of these requirements.
A regimen i is safe if after ni patients∫ 1
φ∗
f
(ni)
t,i (p)dp ≤ ζ(ni) (14)
where f
(ni)
t,i is the Beta posterior density function of the toxicity probability, φ
∗ is the toxicity
threshold and ζni is the probability that controls overdosing. As information increases, we gain
confidence about a regimen’s safety and hence consider the constraint that becomes more strict
as the trial progresses. We therefore use a non-increasing function of ni for ζ
(ni). We choose
ζ(0) = 1 initially to allow all regimens to be tested while the final recommendation is made with
probability ζN . Subsequently we use a linear decreasing function ζ
(ni) = max(1−rtni, ζN ) where
rt > 0. These safety constraint parameters can either be specified by experts or alternatively
calibrated with respect to a trial’s goals using simulations.
4.2 Futility constraint
The same reasoning is applied to a time-varying futility constraint. Regimen i is efficacious if
after ni patients ∫ 1
ψ∗
f
(ni)
e,i (p)dp ≥ ξ(ni) (15)
where f
(ni)
e,i is the Beta posterior density function of the efficacy probability, ψ
∗ is the efficacy
threshold and ξ(ni) is the controlling probability. This probability is an increasing function of
ni and the recommendation is made with probability ξN . We use a linear increasing function
ξ(ni) = min(reni, ξN ) where re > 0.
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Table 2: Six permutations of scenario 1. The optimal regimen is in bold and correct regimens
are underlined.
T1 T2 T3 T4 T5 T6
Scenario 1.1 (.005;.01) (.01;.10) (.02;.30) (.05;.50) (.10;.80) (.15;.80)
Scenario 1.2 (.005;.01) (.01;.10) (.02;.30) (.10;.80) (.05;.50) (.15;.80)
Scenario 1.3 (.005;.01) (.01;.10) (.05;.50) (.02;.30) (.10;.80) (.15;.80)
Scenario 1.4 (.005;.01) (.01;.10) (.10;.80) (.02;.30) (.05;.50) (.15;.80)
Scenario 1.5 (.005;.01) (.01;.10) (.05;.50) (.10;.80) (.02;.30) (.15;.80)
Scenario 1.6 (.005;.01) (.01;.10) (.10;.80) (.05;.50) (.02;.30) (.15;.80)
5 Numerical results
5.1 Setting
In this section we study the performance of the proposed design in the context of the motivat-
ing trial under various different scenarios. Following the motivating trial, we consider M = 6
regimens and N = 36 patients which are enrolled in cohorts of c = 2. The setting as stated in
Section 3.5 remains unchanged. The upper toxicity and the lowest efficacy bounds are φ = 0.35
and ψ = 0.20, respectively. The goal is to study the ability of the WE design to identify the
optimal and correct regimens as defined above.
The major challenge of the motivating trial is the uncertainty in both regimen-toxicity and
regimen-efficacy relations. This increases the number of possible scenarios to be investigated
enormously. Therefore, we start by defining scenarios on which the assessment will be based.
Firstly, we specify 14 scenarios with increasing regimen-toxicity relations and different shapes
of regimen-efficacy curves (Figure 4): eight plateau regimen-efficacy scenarios (1-8) by Riviere
et al. (2016), four umbrella shaped scenarios (9-12) by Wages and Tait (2015), and two scenarios
with no optimal and correct regimens (13-14, due to inefficacy and toxicity, respectively). These
scenarios were originally used to test the WE approach for Phase I/II dose finding designs with
a single TA and compare its performance to the methods by Wages and Tait (2015) and Riviere
et al. (2016). The results of this evaluation are given in the supplementary materials. Secondly,
to allow for the uncertainty in the toxicity ordering, we consider six permutations of each scenario
with respect to toxicity orderings (1). For instance, six permutations of scenario 1 are given in
Table 2. Overall, this results in 84 scenarios that cover a large variety of possibilities and allows
the proposed design to be assessed in the setting of the motivating trial adequately. In the analysis
we focus on (i) the proportion of optimal/correct recommendations, (ii) the average number of
toxic responses, (iii) the average number of efficacy responses. The study is performed using R
(R Core Team, 2015) and 10,000 replications for each scenario. We compare the characteristics
to an extended ‘WT‘ design by Wages and Tait (2015) whose specification is given below.
5.2 Design specification
As in the illustrative example above, we use a target toxicity of γt = 0.01 and a target efficacy
of γe = 0.99. This implies that an investigator targets the most efficacious yet the least toxic
regimen. Due to the partially unknown toxicity ordering, the design was restricted to satisfy
the coherence conditions (11)-(12) with respect to partial orderings and q = 1. The randomized
design is presented here as it has been shown in the evaluations of single agent trials (see sup-
plementary materials) to be have more potential benefits when there is more than one correct
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Figure 4: Eight plateau regimen-efficacy scenarios (1-8), four umbrella regimen-efficacy scenarios
(9-12) and two scenarios with no correct regimens (13-14) in the trial with M = 6 regimens.
Toxicity and efficacy probabilities are marked by red cicles and blue triangles, respectively. Red
horizontal line corresponds to the upper toxicity bound φ = 0.35 and blue dashed horizontal line
coresponds to the lowest efficacy bound ψ = 0.20. Dashed black vertical line corresponds to the
optimal regimen.
regimen expected in the trial.
Parameters βt,i = βe,i = 1 of the prior Beta distributions in (8) are chosen for all regimens
i = 1, . . . , 6 to emphasize a limited amount of information available to clinicians. Parameters νt,i
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and νe,i (which coincide with prior toxicity efficacy probabilities for chosen values of βt,i, βe,i)
are calibrated such that the optimal regimen can be found in various different scenarios with
high probability. Note that the design is fully driven by the values of the trade-off function
and, therefore, there are two requirements to the prior parameters. The prior should dictate
to start the trial at the lowest regimen T1 and the design should follow the escalation order of
regimens specified by clinicians (with no regimen-skipping). To preserve a gradual escalation,
the prior should assume that the higher regimens have greater efficacy, but also greater toxi-
city. To restrict the number of prior parameters to be calibrated, we would assume a linear
increase in prior toxicity and efficacy probabilities. Through extensive calibration, prior vec-
tors of toxicity probabilities pˆ
(0)
t = [0.10, 0.14, 0.18, 0.22, 0.26, 0.30]
T
and efficacy probabilities
pˆ(0)e = [0.60, 0.62, 0.64, 0.66, 0.68, 0.70]
T
were chosen for subsequently analysis in all scenarios.
Note that despite the increasing prior probabilities, the ordering of the regimes is not fixed and
can change as the trial progresses.
Regarding the ethical constraint, parameters of the safety constraint ζN = 0.30, rt = 0.02,
φ∗ = 0.4 and of the futility constraint ξN = 0.50, re = 0.05, ψ∗ = 0.35 were calibrated. Further
guideline on the prior parameters choice together with the calibration of safety and futility
constraints are given in supplementary materials.
We compare the performance of the novel approach to the extension of the WT design by
Wages and Tait (2015). We extend the original WT design to allow the randomization between
toxicity orderings. Following Wages and Tait (2015), a trial with a monotonic regimen-toxicity
relation and 6 regimens is associated with 11 efficacy orderings: one strictly monotonic, five
cases of a plateau location and 5 cases of a umbrella peak. Similarly, one can deduce all possible
efficacy orderings associated with each toxicity ordering. For instance, for the toxicity ordering
T1, T2, T3, T5, T4, T6 we specify
1. 0.10, 0.20, 0.30, 0.50, 0.40, 0.60 (monotonic with respect to regimen-toxicity)
2. 0.20, 0.30, 0.40, 0.60, 0.50, 0.60 (plateau starting at T4)
3. 0.30, 0.40, 0.50, 0.50, 0.60, 0.40 (peak at T5)
4. 0.20, 0.30, 0.40, 0.60, 0.50, 0.50 (peak at T4)
5. 0.40, 0.50, 0.60, 0.40, 0.50, 0.30 (peak at T3)
6. 0.50, 0.60, 0.50, 0.30, 0.40, 0.20 (peak at T2)
7. 0.60, 0.50, 0.40, 0.20, 0.30, 0.10 (peak at T1)
Note that other orderings as a ‘plateau starting at T1/T2/T3/T5‘ are already included in the first
regimen-toxicity case. Applying the same procedure to the rest of toxicity orderings in (1) leads
to 48 efficacy orderings. The design proceeds as follows. Firstly, given the available data, one of
6 toxicity orderings is selected as proposed by Wages et al. (2011). Secondly, one of 48 efficacy
orderings is chosen as in the original design. The parameters of the designs are chosen as in
the original specification by Wages (2015) with an exception of using cohort size c = 2 and 80%
confidence intervals for stopping rules. Note that the WT design waits for both toxicity and
efficacy responses to allocated the next cohort and assumes that an efficacy outcome is observed
regardless the toxicity outcome.
Different variation of the extended WT design were also explored. A reduced number of
efficacy orderings (plateau cases only) were investigated, but no significant difference was found,
and the specification with the full number of orderings was found to be more robust. Additionally,
the ‘conditional‘ choice of the efficacy orderings was also studied. Using this approach, once the
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Table 3: Mean number of toxicity and efficacy responses in scenarios 1−12 across six permutations
using N = 36 patients and M = 6 regimens. Figures corresponding to the best performance are
in bold. The results are based on 104 replicated trials.
Scenario 1 2 3 4 5 6 7 8 9 10 11 12
Toxicity responses
WE(R) 2.5 6.4 3.2 4.4 7.0 7.7 5.1 5.1 3.9 5.9 7.8 2.4
WT 4.1 5.0 4.5 7.1 7.9 8.7 5.9 6.0 3.3 4.2 7.5 1.5
Efficacy responses
WE(R) 19.8 14.4 20.8 19.5 18.2 12.5 22.8 22.8 15.4 13.7 16.7 18.1
WT 24.5 14.4 21.0 21.4 19.0 13.8 23.4 23.5 15.8 14.4 16.7 21.5
toxicity orderings is selected, that choice of the efficacy orderings is restricted to 11 orderings
with respect to the toxicity profile. However, it was found to result in less accurate optimal and
correct regimen recommendations across all scenarios.
5.3 Operating characteristics
The results of the comparison in scenarios 1-12 using 6 permutations are summarized in Figure
5. The length of the bar corresponds to the proportion of the optimal (solid) and correct (trans-
parent) regimen recommendations by WE(R) (black) and WT (red). Overall, both designs are
robust to toxicity ordering permutations under all scenarios. The difference of minimum and
maximum proportions of the optimal and correct recommendations within one scenario does not
exceed 5% and 8% for both designs, respectively. Regarding the proportion of correct recom-
mendations, the designs perform comparably (no more than 5% difference) in scenarios with
several correct regimens (scenarios 2-5, 7 and 8) with scenario 1 being an exception (8% differ-
ence in favour to WT design). Regardless the large number of orderings, WT design preserves
it accuracy in terms of the correct regimen recommendation.
Comparing optimal regimen recommendations, WE(R) favours the optimal regimen over
other correct regimens systematically. It results in superior characteristics in half of all scenarios:
1, 3, 4, 7-9 with the minimum difference across permutations ranging from 7% (scenario 7) up
to 45% (scenario 1) and the maximum difference varying between 11% and 52%, respectively.
Generally, WT is less conservative as it favours safe regimens with higher toxicity that results
in a lower proportion of optimal recommendations in these scenarios. Both designs perform
comparably in scenarios 2, 5, 10 and 11 within the maximum difference of 2-4%. At the same
time, less conservative nature of WT allows to outperform WE(R) by 3-8% under scenario 6
in which the optimal regimen is the highest safe one. WT also shows a better performance in
scenario 12 with difference in the proportion of optimal recommendations ranging in 10-13%.
The regimen 1 is optimal and 36 patients is not enough for WE(R) to investigate all regimens
and come back to T1, but it is enough for the WT to identify the decreasing ordering.
Regarding scenarios 13 and 14 with no correct and no optimal regimens due to futility and high
toxicity, WE(R) terminates the trial earlier in nearly 72% and 85% of the trials against 68% and
79%, respectively. WE(R) results in 10.5 and 10.3 toxic responses on average in scenarios 13 and
14 against 10.4 and 10.5 by WT, respectively. Regarding the efficacy outcomes, WE(R) results
in 7.0 and 8.7 responses versus 7.4 and 9.0 by WT. This follows that both designs are able to
terminate the trial with high probability and prevent unethical patient allocations. Investigating
further ethical aspects of the design, the average numbers of toxicity and efficacy responses across
all permutations in the rest of scenarios are given in Table 3.
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Figure 5: Proportion of optimal (bright) and correct (transparent) recommendsations by WE(R)
(black) and WT (red) designs in scenario 1-12 across six permutations. The results are based on
104 replications.
The WE(R) design is generally more safe and results in at least nearly one less toxic response
in scenarios 1, 3-8 with the largest difference of 2.7 in scenario 4. WT design results in fewer
toxicities in scenarios where the target regimen is among the first ones (scenarios 2, 10, 12).
While the prior toxicity vector chosen for WE(R) suggests to proceed escalation, the model-
based approach is able to identify the correct ordering faster. The average number of efficacy
outcomes does not differ by more than one in the majority of scenarios (2, 3, 5, 7-11). Due to
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Table 4: Operating charsteristics of the WE (R) design in scenarios 1-12: proportion of optimal
and correct recommenations for different values of toxicity and efficacy outcomes correlation
r = {−0.8, 0.0, 0.8}. The largest deviations are in bold. Results are based on 104 replications.
Scenario 1 2 3 4 5 6 7 8 9 10 11 12
WE (R) Proportion of optimal recommendations
ρ = −0.8 70.7 22.5 37.7 59.8 40.0 52.8 36.2 24.7 51.1 45.9 45.1 56.0
ρ = 0.0 66.5 31.0 39.5 59.3 40.5 46.8 33.2 32.8 44.8 47.7 38.5 59.1
ρ = 0.8 65.5 41.2 42.4 61.4 42.7 47.5 33.5 38.3 43.6 51.4 37.3 63.6
Proportion of correct recommendations
ρ = −0.8 90.9 81.2 91.4 91.8 78.0 52.8 91.6 75.4 51.1 45.9 48.1 56.0
ρ = 0.0 88.1 89.7 87.2 86.7 73.2 46.8 86.7 77.5 44.8 47.7 38.5 59.1
ρ = 0.8 88.4 96.6 84.8 84.5 73.6 47.5 86.2 80.9 43.6 51.4 37.3 63.6
fact the WT waits for the complete efficacy response and due to model-based nature, it results
in 1-5 more average efficacy responses in scenarios 1, 4, 6 and 12. At the same time, WE(R)
waits for the efficacy outcome and escalates slower as it was shown in Section 3.5.
Summarizing, the proposed design is robust to the possible true toxicity and efficacy orderings.
WE(R) is found to be a good and comparative alternative to the model-based design when large
number of ordering are to be considered and the randomization might be hard to justify in an
application. While all possible toxicity and efficacy orderings are still feasible to specify, it can
be challenging to convince a clinician to randomize between them given the limited sample size of
N = 36 patients. WE(R) is able to identify optimal and correct regimens with high probability
while being more safe than model-based design and has comparable number of efficacies in
majority of realistic scenarios.
5.4 Sensitivity analysis
In the simulation study above, the toxicity and efficacy outcomes were assumed to be uncorrelated
which may not hold in an actual trial. In this section, we investigate the robustness of the WE(R)
design to the correlation in toxicity and efficacy under scenarios given in Figure 4. The study
was also conducted for different toxicity orderings permutations and the same qualitative results
were obtained (not shown).
We follow the procedure proposed by Tate (1955) to generate correlated binary toxicity and
efficacy outcomes. The procedure generates a binary normal vector with unit variances and
pre-specified correlation coefficient ρ. The generated random variable is then transformed to a
binary response by applying the cumulative distribution function and a quantile transformation,
subsequently.
The results of the WE(R) performance in the case of high negative correlation (ρ = −0.8),
an absence of correlation (ρ = 0.0) and high positive correlation (ρ = 0.8) under scenarios 1-
12 are summarised in Table 4. In the majority of scenarios, WE(R) is robust to both negative
and positive correlations. The differences between the proportion of optimal recommendations in
positively and negatively correlated cases do not exceed 8% in 10 out of 12 scenarios with scenario
2 and 8 being exceptions. Moreover, the proportions of optimal recommendations in correlated
cases never differ by more than 10% compared to the uncorrelated case. A noticeable difference
in the performance can be seen in plateau scenarios 2 and 8 in which the optimal regimens are
among low regimens (T1 and T2, respectively). In these scenarios efficacy probabilities are nearly
the same. The negative correlation biases the recommendations to higher regimens which worsen
the proportion of optimal recommendations by nearly 9% in scenarios 2 and 8. In contrast, the
positive correlation biases selections to lower regimens and leads to an increase by 10% and 6% in
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the proportion of optimal recommendations in these scenarios. There are no noticeable changes
in the rest of scenarios as the bias caused by the correlation is smaller than the difference in true
toxicity and probability estimates.
Overall, the proposed design is robust to the highly correlated toxicity and efficacy outcomes.
The proportion of optimal and correct recommendations in the correlated cases never differs
by more than 10% compared to the uncorrelated case. Despite assumed independence in the
estimates, WE(R) is able to find the optimal and correct regimens in highly correlated cases.
6 Conclusions
In this article, we have introduced a novel phase I/II design for molecularly targeted agents that
does not require an assumption of monotonicity. The proposed design is based on the simple
and intuitively clear trade-off function which can be easily computed by non-statisticians. The
simulation results demonstrate that the novel approach can identify the optimal regimen with
high probability and leads to ethical patient allocations. Therefore, it can be recommended for
the clinical application with a limited sample size and missing, delayed efficacy responses. The
novel design is applied to the challenging combination-schedule trial with uncertainty in both
toxicity and efficacy ordering. The proposal is shown to be a good alternative to the model-based
designs when the ordering specification is challenging.
In this paper we have considered the setting where efficacy can only be observed if no toxicity
is observed in a patient. At the same time, a setting with four possible outcomes can be also
considered using the same information-theoretic approach. The only difference is the form of
the Dirichlet distribution (2) which is used to obtain the trade-off function (Mozgunov and
Jaki, 2017). Additionally, the influence of various techniques of the missing and delayed efficacy
outcomes implementation can be of interest in a setting with no parametric model. While binary
outcomes are considered only, a continuous efficacy endpoint becomes more common choice in a
clinical practice. An extension of the proposed design for a this case is the subject to a future
research.
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Supplementary Materials
7 Application of WE design to a single-agent trial
The proposed design can be applied to a wide range of Phase I/II clinical trials. While the
performance of the WE design is demonstrated in the context of the motivating trial, it can
be also applied to a single agent dose-finding trial for which several model-based designs were
recently proposed (see e.g. Wages and Tait, 2015; Riviere et al., 2016). Here we show the
comparison of the proposed design to the currently used and provide a step-by-step algorithm
how the parameters of the proposed design can be calibrated.
7.1 Simulation setting
We consider M = 6 doses and N = 60 patients. The dose-toxicity relationship is known to
be a non-decreasing function, but a clinician expects either a plateau or an umbrella shape for
the dose-efficacy curve. A toxicity is evaluated after three weeks while an efficacy outcome is
evaluated after six weeks. To conduct the trial in a timely manner, the next cohort of patients
is allocated after the toxicity data for previous cohort are available. The upper toxicity and
the lowest efficacy bounds are φ = 0.35 and ψ = 0.20. The goal is to study the ability of the
WE design to identify the optimal and correct doses. A dose is called optimal if it is safe, has
maximal efficacy and minimal toxicity while a safe dose with maximum efficacy (irrespective of
it also having lowest toxicity) is called correct.
We consider 14 scenarios that were used for the motivating trial simulations: eight plateau
scenarios (1-8) suggested by Riviere et al. (2016), 4 umbrella shaped scenarios (9-12) studied
in Wages and Tait (2015) and two scenarios with no correct doses (13-14, due to inefficacy and
toxicity, respectively) − see Figure 4 in the main paper.
In the analysis we focus on (i) the proportion of optimal/correct recommendations, (ii) the
average number of toxic responses, (iii) the average number of efficacy responses. The study is
performed using R (R Core Team, 2015) and 10,000 replications for each scenario. We compare
the characteristics with the ‘MTA‘ design proposed by Riviere et al. (2016) and the ‘WT‘ design
developed by Wages and Tait (2015). Parameters of the designs are chosen as in the original
proposals with an exception of using cohort size c = 3 and 80% confidence intervals for stopping
rules for the WT design.
7.2 Design specification
As before, we use a target toxicity of γt = 0.01 and a target efficacy of γe = 0.99. Due to the
known toxicity ordering, the design is restricted to satisfy the coherence principals with q = 1.
While we consider both non-randomized and randomized versions of the WE design to study an
allocation rule impact, the design specification for the non-randomized WE design is provided
only.
7.2.1 Prior
Parameters βt,i = βe,i = 1 of the prior Beta distribution in (8) are chosen for all dose levels
i = 1, . . . ,M to emphasize a limited available information. Parameters νt,i and νe,i (which
coincide the prior probabilities of toxicity and efficacy for βt,i = βe,i = 1) are specified such that
the WE design leads to accurate optimal dose recommendation in various different scenarios.
The prior values of νt,i and νe,i are calibrated over scenarios 1-8 with different locations of the
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optimal and correct doses. There are two restrictions on the prior parameters: the escalation
should start at the first dose and no dose skipping is allowed. To restrict number of possible
parameters to be calibrated over, we assume that prior efficacy and toxicity probability increases
linearly as νt,i = startt + wt × i and νe,i = starte + we × i. Then, we search for the values of
startt, starte, wt, we such that the geometric mean of the proportion of optimal selection over all
scenarios is maximised.
Prior vectors of toxicity probabilities pˆ
(0)
t = [0.05, 0.14, 0.23, 0.32, 0.41, 0.50]
T
and efficacy
probabilities pˆ(0)e = [0.55, 0.58, 0.61, 0.64, 0.67, 0.70]
T
are subsequently used for the non-randomized
WE design.
Similarly, vectors of prior toxicity
pˆ
(0)
t = [0.25, 0.35, 0.45, 0.55, 0.65, 0.75]
T
and
pˆ(0)e = [0.65, 0.69, 0.73, 0.77, 0.81, 0.85]
T
efficacy probabilities are used for the randomized WE(R) design. It was found that the ran-
domised WE(R) design is more robust to the choice of the prior parameter than non-randomised
WE.
7.2.2 Safety constraint
To set the time-varying safety constraint, we use ζN = 0.30 and calibrate φ
∗, rt using the highly
toxic scenario 14 and the flat scenario 6. These two scenarios are chosen to represent the trade-off
in the safety constraint. The proportion of correct recommendations (terminations) and mean
number of patients involved in a trial for different parameters values are given in Figure 6. The
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Figure 6: Safety constraint parameters calibration: φ∗ ∈ (0.3, 0.5), rt ∈ (0, 0.05) in scenarios
6 and 14. The proportion of correct recommendations (terminations) and the mean number of
patients in a trial (scenario 14). The final choice is marked by a black frame. Results are based
on 104 replications.
mean number of patients in scenario 6 does not vary a lot and the corresponding graph is not
shown. In scenario 6 the highest proportion of the optimal recommendations corresponds to
the least strict safety constraint (right bottom corner), but only 35% of trials in scenario 14 are
then terminated. At the same time, the most strict rule (left top corner) results in 100% of
terminations in scenario 14, but only in 5% of correct recommendation in scenario 6. Parameters
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rt = 0.0125 and φ
∗ = 0.4 are chosen for subsequent study as a reasonable trade-off. The same
parameters of the safety constraints are used for the randomized design.
7.2.3 Futility constraint
We calibrate the futility constraint by fixing ξN = 0.50 and tuning ψ
∗ and re using two opposite
scenarios - 2 and 13. In scenario 2 all doses have the same efficacy probability. In scenario 13
there are no correct doses as all efficacious doses have unacceptable toxicity. The proportion of
correct recommendations (terminations) and the mean number of patients are given in Figure 7.
Since the mean number of patients in scenario 2 does not vary this graph is not shown. A stricter
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Figure 7: Futility constraint parameters calibration: ψ∗ ∈ (0.1, 0.5) and re ∈ (0, 0.05) in scenarios
2 and 13. The proportion of correct recommendations (terminations) and the mean number of
patients in a trial (scenario 13). The final choice is in the black frame. Results are based on 104
replications.
constraint is favourable in scenario 13 and less favourable in scenario 2 while the opposite is true
for less strict constraints. Subsequently, parameters ψ∗ = 0.3 and re = 0.05 are used for both
non-randomized and randomized designs.
7.3 Operating characteristics
The results of the comparison in scenarios 1-8 with plateau dose-efficacy relation and in scenarios
13-14 with no correct doses are summarized in Table 5 and Table 6. Each figure in Table 5
corresponds to proportions of optimal or correct dose recommendations. The detailed results,
such as the selection proportions and mean number of patients on each dose, are given in Table
9 and Table 11 in Appendix.
With respect to the optimal dose recommendation, both versions of the proposed design
perform comparably or better than model-based designs in the majority of scenarios. The WE
design without randomization leads to a considerable improvement in scenarios 3-5, 7 and 13-14
and outperform the best model-based alternative by up to 20%. While the randomized WE(R)
shows the comparable to the best model-based alternative performance in scenarios 3,5 and 6, it
also results in more accurate optimal dose recommendations in scenarios 1, 4, 7, 13-14. However,
both WE and WE(R) are outperformed by MTA in scenarios 2 and 8 in which dose-toxicity and
dose-efficacy curves are flat in the neighbourhood of the optimal dose. While MTA recommends
the lowest dose by default, such small differences in toxicity and efficacy probabilities are difficult
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Table 5: Proportion of optimal and correct dose recommendations in scenarios 1-8 and 13-14
using N = 60 patients and M = 6 doses for all considered designs. Figures corresponding to the
highest performance in each scenario are in bold. The results are based on 104 replicated trials.
Scenario 1 2 3 4 5 6 7 8 13 14
Proportion of the optimal dose recommendation
WE 58.8 30.3 65.8 71.1 60.3 53.5 60.0 37.8 95.2 96.9
WE (R) 72.0 35.0 51.0 69.9 54.5 56.7 48.5 36.4 93.2 97.4
MTA 57.0 60.2 48.4 53.7 55.3 55.9 37.9 43.0 91.9 91.0
WT 19.6 41.9 29.3 25.3 27.0 65.2 27.1 26.1 91.5 90.4
Proportion of the correct dose recommendation
WE 60.3 90.0 87.5 79.8 89.7 53.5 77.8 91.5 - -
WE (R) 89.3 97.0 92.8 89.1 87.5 56.7 88.3 91.1 - -
MTA 94.1 96.6 83.8 82.3 80.6 55.9 89.9 77.4 - -
WT 98.1 97.6 93.6 86.5 80.0 65.2 93.3 81.1 - -
to find the small sample size. At the same time, the absence of a parametric model is not found
to be a problem in any other cases. WT design outperforms all other designs in scenario 6 with
the optimal dose being the highest safe one. Generally, WT is less conservative as it favours safe
doses with higher toxicities that results in a low proportion of optimal recommendations if the
optimal dose is not the highest safe one (see also Table 9 and Table 11).
Considering the proportion of the correct recommendations, WT outperforms MTA in all
scenarios and has the best performance among all alternatives in scenarios 1-3 and 6-7. In the
rest of scenarios WT has either comparable or worse performance than the randomized WE(R).
Comparing WE and WE(R), the randomized design is more robust in the correct recommenda-
tions with a largest difference in scenario 1. Here, the chosen prior would not escalate to dose 6
once the optimal is already find at dose 5 if no randomization is used.
In terms of toxicities we find that the non-randomized WE design results in considerably
lower number of toxicities in almost all scenarios with the largest difference observed in scenario
4. As the WT approach is less conservative, it results in a greater number of toxicities, but
also leads to the highest average number of efficacies in all scenarios. In contrast, the cost of
the WE’s lowest number of toxicities is a smaller number of efficacies. In scenarios 13 and 14
with no optimal and correct doses all alternatives result in nearly the same average number of
toxicities and efficacies.
The results of the comparison in scenarios 9-12 with an umbrella shaped dose-efficacy rela-
tionship and only one correct dose are given in Table 7. Overall, WE designs have more robust
optimal dose identification in non-monotonic scenarios. The WE design with no randomization
outperforms MTA by up to 35% and WT by up to 6%. WT has the highest proportion of the op-
timal dose recommendations in scenarios 11 with nearly 10% difference with the non-randomized
WE. The MTA design is more conservative and recommends d1 with the highest probability
that results in the best performance in scenario 12, but poor performance in other cases. The
non-randomized WE is favourable compared to the randomized version due to the single correct
dose in each scenario. The average number of toxicities of the WE design is again the safest
alternative. In contrast to the scenarios with plateau, it can now also result in a larger number
of efficacy responses (e.g. in scenario 9) due to the non-monotonic shape of the dose-efficacy
curve.
Overall, the proposed approaches have better or comparable operating characteristics in 9 out
of 14 considered scenarios even with less information used in a trial. Comparing two assignment
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Table 6: Mean number of toxicity and efficacy responses in scenarios 1 − 8 and 13 − 14 using
N = 60 patients and M = 6 doses for all considered designs. The results are based on 104
replicated trials.
Scenario 1 2 3 4 5 6 7 8 13 14
Toxicity responses
WE 3.1 6.0 2.8 4.5 7.9 11.0 5.9 5.6 11.7 11.0
WE (R) 4.0 6.9 4.3 6.0 8.7 10.8 6.9 6.9 13.0 10.9
MTA 5.5 8.1 6.0 10.0 12.1 13.2 9.6 9.3 11.0 11.5
WT 6.8 6.7 7.3 13.2 13.5 14.7 10.0 9.1 11.2 12.1
Efficacy responses
WE 28.5 24.0 33.0 30.0 29.8 19.4 34.6 28.9 6.0 9.1
WE (R) 27.4 24.0 34.5 32.2 29.8 19.2 36.5 29.2 7.1 8.9
MTA 38.0 24.0 34.6 35.0 29.4 21.4 39.1 29.3 6.2 9.6
WT 41.5 24.0 35.5 37.0 32.3 24.4 39.9 29.2 5.4 9.7
Table 7: Proportion of optimal dose recommendations, mean number of toxicity and efficacy
responses in scenarios 9-12 using N = 60 patients and M = 6 doses for all considered designs.
The results are based on 104 replicated trials.
Scenario 9 10 11 12 9 10 11 12 9 10 11 12
Optimal recommendation Toxicity responses Efficacy responses
WE 54.7 55.9 46.5 80.1 4.5 5.7 10.0 1.8 29.7 25.6 27.4 35.4
WE (R) 56.7 56.2 47.9 70.9 5.5 6.7 10.0 3.3 28.4 24.6 27.1 32.7
MTA 20.3 35.3 46.0 96.1 5.0 6.3 12.8 2.6 26.3 23.9 28.7 35.5
WT 50.1 49.3 56.9 75.9 5.5 5.9 12.2 2.4 27.9 24.8 29.4 36.3
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rule of the WE design, the non-randomized WE is always less accurate in terms of the correct
dose identification. As the result, the WE design without randomization should be preferred
if only one correct dose is expected or a clinician is cautious about toxicity profile, while the
randomized WE is a robust choice if multiple correct doses are expected.
7.4 Early efficacy data
In the setting above, it is assumed that it takes twice as long to observe the efficacy outcome
than the toxicity endpoint. It is, however, possible that an efficacy (or lack of efficacy) can be
observed at the time of the interim analysis for some of the patients. As the proposed design
includes all available information, it can also accommodate earlier efficacy (no efficacy) data.
This section we study how the operating characteristics of the non-randomised WE design are
affected if a certain proportion of ‘no efficacy‘ responses can be observed earlier.
The setting above remains unchanged with the following exception: if the patient has observed
no DLT and will have ‘no efficacy ‘, it is assumed that the outcome can be observed at the time
of toxicity evaluation with probability pi. If observed earlier, the WE design uses this information
for the next patient allocation. We consider two cases: pi = 0 (the original setting) and pi = 1/2
(half of ‘no efficacies‘ can be seen earlier). The results are given in Table 8.
As expected, the availability of some of the efficacy information earlier leads to a less con-
servative design that allows more rapid escalation. Earlier ‘no efficacy‘ data even in half of
the patients lead to more ethical patient allocation. This can be seen by increased numbers of
efficacies almost in all scenarios with the cost of reasonable increase in the average number of
toxicity responses. The largest increase can be seen in scenario 1 where the average number of
efficacy response increase by nearly 7, while toxicity increases only by 1. The information about
earlier efficacy also improves the proportion of optimal recommendations in the scenarios where
the target dose is high - by 6% in scenario 1 and by 4% in scenario 6. As the design being less
conservative it favours higher doses among correct ones. This decreases the proportion of optimal
recommendations in scenario 3, 5, 7 and 12 by 3-7%. At the same time, the proportion of correct
recommendations is either unchanged (scenario 5 and 8) or increased by at least 5% (all the
rest plateau scenarios). This confirms that the WE design in the setting with no earlier efficacy
information is more conservative, but the difference in correct selection is relatively small.
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Table 8: Operating characteristics of WE in scenarios 1-12 with no early efficacy data available
(pi = 0) and with half ‘no efficacy‘ outcomes (pi = 1/2) available at the time of toxicity evaluation:
recommendation proportions, mean number of toxicity (T) and efficacy (E) responses . The
optimal dose is in bold and correct doses are underlined. Results are based on 104 replications.
WE d1 d2 d3 d4 d5 d6 T E
Scenario 1
(.005;.01) (.01;.10) (.02;.30) (.05;.50) (.10;.80) (.15;.80)
pi = 0 0.0 0.1 2.3 37.4 58.8 1.5 3.1 28.5
pi = 1/2 0.0 0.0 1.5 23.5 64.9 10.0 4.3 34.8
Scenario 2
(.01;.40) (.04;.40) (.10;.40) (.25;.40) (.50;.40) (.70;.40)
pi = 0 30.3 26.3 20.8 12.5 6.3 3.7 6.0 24.0
pi = 1/2 33.2 27.1 21.9 12.2 3.7 1.6 7.2 24.0
Scenario 3
(.01;.25) (.02;.45) (.05;.65) (.10;.65) (.20;.65) (.30;.65)
pi = 0 0.6 12.6 65.8 18.2 2.8 0.1 2.8 33.0
pi = 1/2 0.9 9.4 57.7 24.0 6.8 1.1 3.7 34.8
Scenario 4
(.01;.05) (.02;.25) (.05;.45) (.10;.70) (.25;.70) (.50;.70)
pi = 0 0.0 0.5 19.6 71.1 8.5 0.3 4.5 30.0
pi = 1/2 0.0 0.9 14.6 68.0 15.8 0.7 5.9 33.9
Scenario 5
(.01;.10) (.05;.35) (.15;.60) (.20;.60) (.45;.60) (.60;.60)
pi = 0 0.1 6.2 60.3 28.9 3.6 0.8 7.9 29.8
pi = 1/2 0.1 6.3 56.8 32.8 3.3 0.7 9.2 31.5
Scenario 6
(.01;.05) (.05;.10) (.10;.20) (.20;.35) (.30;.55) (.50;.55)
pi = 0 0.4 0.8 3.7 18.9 53.5 18.9 11.0 19.4
pi = 1/2 1.4 1.4 4.9 22.2 57.2 10.0 13.1 22.2
Scenario 7
(.02;.30) (.07;.50) (.13;.70) (.17;.73) (.25;.76) (.30;.77)
pi = 0 0.5 21.4 60.0 16.2 1.7 0.0 5.9 34.6
pi = 1/2 0.9 16.4 53.4 23.2 5.5 0.6 6.9 37.0
Scenario 8
(.03;.30) (.06;.50) (.10;.52) (.20;.54) (.40;.55) (.50;.55)
pi = 0 3.2 37.8 34.7 19.1 4.2 1.0 5.6 28.9
pi = 1/2 3.0 37.8 34.0 20.1 4.0 1.1 6.9 29.5
Scenario 9
(.01;.30) (.05;.50) (.10;.60) (.15;.40) (.20;.25) (.25;.15)
pi = 0 3.0 34.7 54.7 5.8 1.3 0.5 4.4 29.7
pi = 1/2 3.8 34.2 54.6 6. 1.1 0.2 5.1 29.7
Scenario 10
(.02;.38) (.06;.50) (.12;.40) (.30;.30) (.40;.25) (.50;.20)
pi = 0 18.4 55.9 15.9 3.9 3.2 2.7 5.7 25.6
pi = 1/2 20.2 57.1 17.2 2.8 1.6 1.0 6.3 25.5
Scenario 11
(.03;.25) (.09;.35) (.16;.48) (.28;.65) (.42;.52) (.56;.39)
pi = 0 2.2 9.8 30.4 46.5 8.6 2.8 10.0 27.4
pi = 1/2 3.5 10.8 31.7 45.5 6.3 1.8 11.4 28.8
Scenario 12
(.02;.68) (.05;.56) (.07;.49) (.09;.40) (.11;.33) (.13;.26)
pi = 0 80.1 14.5 3.9 1.1 0.3 0.1 1.8 35.4
pi = 1/2 74.1 17.5 5.8 1.8 0.6 0.1 2.2 36.8
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Table 9: Operating charsteristics of WE, WE(R), MTA and WT design in scenarios 1-5: recom-
mendation proportions, mean number of patients assigned to a dose (in brackets), termination
proportion (Term), mean number of toxicity (T) and efficacy (E) respones. The optimal dose is
in bold and correct doses are underlined. Results are based on 104 replications.
d1 d2 d3 d4 d5 d6 Term T E
Scenario 1
(.005;.01) (.01;.10) (.02;.30) (.05;.50) (.10;.80) (.15;.80)
WE 0.0 0.1 2.3 37.4 58.8 1.5 0.0 3.1 28.5
(6.1) (6.3) (9.5) (20.5) (17.4) (0.3)
WE(R) 0.0 0.2 1.0 9.5 72.0 17.3 0.0 4.0 27.4
(5.1) (5.0) (8.2) (13.8) (21.7) (6.2)
MTA 0.0 0.0 0.7 4.5 57.0 37.1 0.7 5.5 38.0
(3.3) (3.7) (4.8) (7.7) (21.5) (19.0)
WT 0.0 0.1 0.4 1.3 19.6 78.5 0.1 6.8 41.5
(3.9) (1.6) (2.4) (3.6) (11.4) (37.1)
Scenario 2
(.01;.40) (.04;.40) (.10;.40) (.25;.40) (.50;.40) (.70;.40)
WE 30.3 26.3 20.8 12.5 6.3 3.7 0.2 6.0 24.0
(18.3) (17.0) (13.7) (7.9) (2.7) (0.4)
WE(R) 35.0 29.0 21.5 11.5 2.8 0.2 0.1 6.9 24.0
(15.0) (15.7) (15.7) (10.0) (3.3) (0.4)
MTA 60.2 20.3 8.8 7.3 2.6 0.3 0.6 8.1 24.0
(18.8) (13.0) (10.7) (10.7) (5.8) (0.8)
WT 41.9 24.5 16.9 14.2 2.4 0.0 0.0 6.7 24.0
(23.1) (13.0) (10.7) (8.6) (3.4) (1.3)
Scenario 3
(.01;.25) (.02;.45) (.05;.65) (.10;.65) (.20;.65) (.30;.65)
WE 0.6 12.6 65.8 18.2 2.8 0.1 0.0 2.8 33.0
(7.2) (15.9) (29.2) (6.7) (0.9) (0.0)
WE(R) 0.7 6.6 51.0 30.5 10.6 1.2 0.0 4.3 34.5
(6.4) (9.6) (21.3) (16.1) (5.8) (0.9)
MTA 2.0 14.3 48.4 19.2 9.8 6.4 0.0 6.0 34.6
(6.3) (9.8) (15.5) (12.9) (10.4) (5.1)
WT 1.4 4.9 29.3 29.9 22.6 11.8 0.0 7.3 35.5
(6.1) (5.0) (13.8) (14.8) (12.0) (8.3)
Scenario 4
(.01;.05) (.02;.25) (.05;.45) (.10;.70) (.25;.70) (.50;.70)
WE 0.0 0.5 19.6 71.1 8.5 0.3 0.0 4.5 30.0
(6.2) (7.9) (17.8) (25.2) (2.9) (0.1)
WE(R) 0.0 1.3 9.2 69.9 18.5 1.0 0.0 6.0 32.2
(5.4) (6.9) (13.4) (24.1) (9.2) (0.8)
MTA 0.0 0.7 8.2 53.7 28.6 8.5 0.4 10.0 35.0
(3.8) (5.0) (9.1) (19.0) (15.9) (7.0)
WT 0.0 0.4 2.1 25.3 61.2 10.8 0.2 13.2 37.0
(4.5) (2.4) (4.0) (13.5) (24.7) (10.9)
Scenario 5
(.01;.10) (.05;.35) (.15;.60) (.20;.60) (.45;.60) (.60;.60)
WE 0.1 6.2 60.3 28.9 3.6 0.8 0.1 7.9 29.8
(6.4) (12.3) (29.4) (10.5) (1.3) (0.1)
WE(R) 0.1 7.3 54.5 35.4 4.2 0.2 0.3 8.7 29.8
(6.1) (12.9) (23.0) (14.8) (3.0) (0.2)
MTA 0.0 8.5 55.3 25.3 9.7 1.2 0.1 12.1 29.4
(5.0) (8.7) (18.5) (15.6) (10.1) (2.0)
WT 0.1 2.7 27.0 53.0 16.9 0.2 0.1 13.5 32.3
(5.2) (4.4) (14.3) (22.3) (11.0) (2.8)
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Table 10: Operating charsteristics of WE, WE(R), MTA and WT design in scenarios 6-10: rec-
ommendation proportions, mean number of patients assigned to a dose (in brackets), termination
proportion (Term), mean number of toxicity (T) and efficacy (E) respones. The optimal dose is
in bold and correct doses are underlined. Results are based on 104 replications.
d1 d2 d3 d4 d5 d6 Term T E
Scenario 6
(.01;.05) (.05;.10) (.10;.20) (.20;.35) (.30;.55) (.50;.55)
WE 0.4 0.8 3.7 18.9 53.5 18.9 4.7 11.0 19.4
(6.6) (7.4) (10.0) (15.7) (16.8) (2.8)
WE(R) 0.4 0.8 4.8 25.4 56.7 7.1 4.4 10.8 19.2
(6.3) (7.7) (11.1) (16.3) (15.2) (2.9)
MTA 0.1 0.7 4.5 17.0 55.9 13.7 8.3 13.2 21.4
(4.5) (5.5) (7.9) (12.4) (19.0) (7.8)
WT 0.2 0.9 3.8 21.4 65.2 5.8 2.7 14.7 24.4
(5.0) (3.0) (5.3) (13.0) (25.1) (7.9)
Scenario 7
(.02;.30) (.07;.50) (.13;.70) (.17;.73) (.25;.76) (.30;.77)
WE 0.5 21.4 60.0 16.2 1.7 0.0 0.0 5.9 34.6
(8.7) (20.6) (25.3) (5.1) (0.4) (0.0)
WE(R) 0.8 10.9 48.5 31.9 7.2 0.6 0.0 6.9 36.5
(8.6) (13.8) (22.0) (12.5) (2.9) (0.3)
MTA 1.4 8.7 37.9 24.5 16.4 11.1 0.0 9.6 39.1
(6.2) (8.9) (14.6) (14.0) (11.3) (5.1)
WT 1.6 5.2 27.1 29.8 24.7 11.7 0.0 10.0 39.9
(6.7) (5.4) (13.7) (14.8) (12.1) (7.3)
Scenario 8
(.03;.30) (.06;.50) (.10;.52) (.20;.54) (.40;.55) (.50;.55)
WE 3.2 37.8 34.7 19.1 4.2 1.0 0.0 5.6 28.9
(9.4) (23.9) (17.8) (7.1) (1.5) (0.1)
WE(R) 3.9 36.4 33.8 20.9 4.4 0.4 0.0 6.9 29.2
(9.2) (16.9) (18.7) (11.7) (3.2) (0.3)
MTA 12.8 43.0 21.7 12.7 8.2 1.7 0.1 9.3 29.3
(10.1) (14.3) (12.8) (12.3) (8.5) (2.0)
WT 7.1 26.1 27.0 28.0 11.3 0.4 0.0 9.1 29.2
(9.9) (13.0) (13.9) (13.8) (7.1) (2.2)
Scenario 9
(.01;.30) (.05;.50) (.10;.60) (.15;.40) (.20;.25) (.25;.15)
WE 3.0 34.7 54.7 5.8 1.3 0.5 0.0 4.4 29.7
(8.9) (23.1) (22.5) (3.9) (1.4) (0.4)
WE(R) 4.1 31.4 56.7 6.5 1.1 0.1 0.0 5.5 28.4
(8.5) (15.6) (22.0) (9.1) (3.6) (1.2)
MTA 24.2 54.7 20.3 0.6 0.0 0.0 0.2 5.0 26.3
(13.2) (18.3) (14.1) (8.5) (4.7) (1.2)
WT 7.3 30.9 50.1 8.8 2.1 0.7 0.2 5.5 27.9
(9.8) (15.4) (22.1) (7.1) (3.3) (2.2)
Scenario 10
(.02;.38) (.06;.50) (.12;.40) (.30;.30) (.40;.25) (.50;.20)
WE 18.4 55.9 15.9 3.9 3.2 2.7 0.1 5.7 25.6
(14.7) (27.4) (11.0) (4.3) (2.1) (0.5)
WE(R) 22.7 56.2 17.0 2.5 1.2 0.2 0.1 6.7 24.6
(13.4) (21.4) (14.9) (6.6) (3.0) (0.6)
MTA 60.4 35.3 2.8 0.4 0.1 0.1 1.0 6.3 23.9
(20.2) (17.6) (10.1) (8.0) (3.3) (0.5)
WT 29.0 49.3 15.8 4.9 0.9 0.1 0.1 5.9 24.8
(19.5) (21.6) (10.5) (4.8) (2.3) (1.2)
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Table 11: Operating charsteristics of WE, WE(R), MTA and WT design in scenarios 11-14:
recommendation proportions, mean number of patients assigned to a dose (in brackets), termi-
nation proportion (Term), mean number of toxicity (T) and efficacy (E) respones. The optimal
dose is in bold and correct doses are underlined. Results are based on 104 replications.
d1 d2 d3 d4 d5 d6 Term T E
Scenario 11
(.03;.25) (.09;.35) (.16;.48) (.28;.65) (.42;.52) (.56;.39)
WE 2.2 9.8 30.4 46.5 8.6 2.8 0.2 10.0 27.4
(9.3) (13.5) (19.4) (15.1) (2.4) (0.3)
WE(R) 3.6 12.0 30.9 47.9 5.3 0.5 0.2 10.0 27.1
(10.2) (13.9) (18.0) (14.5) (3.0) (0.2)
MTA 6.7 14.0 27.0 46.0 5.6 0.3 0.3 12.8 28.7
(8.1) (10.2) (14.1) (17.0) (8.7) (1.7)
WT 6.9 9.4 23.2 56.9 3.5 0.0 0.1 12.2 29.4
(9.9) (7.9) (13.8) (22.2) (4.6) (1.6)
Scenario 12
(.02;.68) (.05;.56) (.07;.49) (.09;.40) (.11;.33) (.13;.26)
WE 80.1 14.5 3.9 1.1 0.3 0.1 0.0 1.8 35.4
(44.8) (10.0) (3.4) (1.1) (0.5) (0.1)
WE(R) 70.9 18.7 7.1 2.4 0.9 0.2 0.0 3.3 32.7
(20.5) (15.1) (11.8) (7.0) (3.6) (1.9)
MTA 96.1 3.2 0.6 0.1 0.0 0.0 0.0 2.6 35.5
(34.6) (10.1) (6.4) (4.8) (2.8) (1.4)
WT 75.9 17.1 5.1 1.2 0.6 0.2 0.0 2.4 36.3
(37.0) (11.0) (5.4) (3.0) (2.1) (1.4)
Scenario 13
(.05;.01) (.10;.02) (.25;.05) (.55;.35) (.70;.55) (.90;.70)
WE 0.0 0.0 0.2 2.9 0.6 1.1 95.2 11.7 6.0
(6.7) (7.6) (10.9) (12.2) (1.6) (0.1)
WE(R) 0.1 0.0 0.2 4.4 1.1 0.2 93.9 13.0 7.1
(6.9) (7.7) (10.6) (12.1) (3.2) (0.4)
MTA 0.0 0.0 2.3 5.8 0.0 0.0 91.9 11.0 6.2
(5.8) (5.9) (7.7) (11.0) (2.7) (0.3)
WT 0.0 0.1 5.5 3.1 0.0 0.0 91.5 11.2 5.4
(6.3) (6.5) (14.8) (7.9) (1.5) (1.2)
Scenario 14
(.50;.40) (.60;.55) (.69;.65) (.76;.65) (.82;.65) (.89;.65)
WE 2.2 0.2 0.1 0.3 0.2 0.0 96.9 11.0 9.1
(17.6) (2.8) (0.6) (0.1) (0.0) (0.0)
WE(R) 1.9 0.5 0.3 0.2 0.0 0.0 97.4 10.9 8.9
(17.6) (2.4) (0.8) (0.1) (0.0) (0.0)
MTA 8.8 0.2 0.0 0.0 0.0 0.0 91.0 11.5 9.6
(16.0) (4.3) (1.1) (0.2) (0.0) (0.0)
WT 9.5 0.0 0.0 0.0 0.0 0.0 90.4 12.1 9.7
(23.0) (0.4) (0.1) (0.1) (0.1) (0.1)
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